Eli Lilly's stock surged in premarket trading following positive results from a Phase 3 trial of its next-generation weight-loss drug, retatrutide. Presented at the American Diabetes Association conference, the trial showed that patients lost an average of 28.3% of their body weight after 80 weeks on the highest dose, and 19% on the lowest dose. This impressive efficacy suggests retatrutide could see wider use than previously expected, potentially impacting the weight-loss drug market significantly.
Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which coul...
A curated list of 50 high-quality dividend growth stocks has been tracked since September 1, 2024, focusing on valuation and future return potential. Year-to-date, this group underperformed broad indexes but included standout performers like LRCX and...
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
The Dow Jones Industrial Average reached a new record after a 2% gain, with the S&P 500 also rising 0.4%. Healthcare stocks led the market rally, driven by strong gains in insurers like Humana and Centene, and drugmakers such as UnitedHealth Group an...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by ...
